Factor

Cerus Corporation to Release Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022

Retrieved on: 
Tuesday, February 8, 2022
Medical Supplies, Medical Devices, Health, General Health, Pharmaceutical, Biotechnology, Factor, Plasma, Bleeding, Company, Investor relations, FDA, Hospital, Patient, Corporation, Cryoprecipitate, CE, CERS, Nasdaq, Webcast, LinkedIn, Online shopping, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Companys financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Cerus Corporation to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Monday, February 7, 2022
General Health, Other Health, Hospitals, Health, Medical Supplies, Factor, Plasma, Bleeding, Conference, Company, Digital health, FDA, Hospital, Patient, Corporation, Cryoprecipitate, EST, Medtech, CERS, Nasdaq, Webcast, LinkedIn, Pharmaceutical industry, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference.
  • On Wednesday, February 16th at 9:00 a.m. EST, Vivek Jayaraman, Cerus chief operating officer, is scheduled to participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference.
  • To listen to the webcast, please visit the investor relations section of Cerus website at: ir.cerus.com.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Factor Expands Chicago Presence with Opening of New Lake Zurich Fulfillment Center

Retrieved on: 
Tuesday, February 1, 2022
Online Retail, Retail, Food, Beverage, Aurora, CEO, Village, Lunch, Organization, McDonald House, Snack, American Cancer Society, HelloFresh, Breakfast, Board, Partnership, Director, Health, Family, Ronald, Foot, Protein, Multimedia, Restaurant, Factor, Trustee

Factor , Americas leading ready-to-eat meal delivery service, announced today the opening of a new fulfillment and distribution center located in Lake Zurich, IL.

Key Points: 
  • Factor , Americas leading ready-to-eat meal delivery service, announced today the opening of a new fulfillment and distribution center located in Lake Zurich, IL.
  • View the full release here: https://www.businesswire.com/news/home/20220201005149/en/
    Lake Zurich Fulfillment Center (Photo: Business Wire)
    This new distribution center bolsters Factors already strong operational presence in Chicago, which includes production facilities in Aurora and Burr Ridge, a distribution center in Lyons, and corporate offices in Batavia.
  • On behalf of myself and the Board of Trustees, I am pleased to welcome Factor to the family of companies choosing to set up shop in Lake Zurich, said Lake Zurich Mayor Tom Poynton.
  • Factor.

Global Hemophilia Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 19, 2022
Pharmaceutical, Genetics, Health, Other Health, BioMarin Pharmaceutical, Patient, Research, Haemophilia A, Bleeding, Coagulation, NHF, Growth, BMN, DNA, World Federation of Hemophilia, Factor, Genzyme, Association, World government, National Health Federation, Coagulopathy, FDA, Prevalence, Awareness, Vaccine, Pharmaceutical industry, Haemophilia

Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding.

Key Points: 
  • Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding.
  • According to the data published by the World Federation of Hemophilia in 2019, hemophilia is more recorded among males, and approximately 24.6 in 100.000 neonates suffer from hemophilia A.
  • According to the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States.
  • In the United States, agencies, like hemophilia Association of America, generally offers continuous treatment for patients by introducing different co-pay initiatives.

NICE and Magnet Forensics Partner to Digitally Transform Police Case Building and Investigations

Retrieved on: 
Wednesday, January 19, 2022
Law Enforcement, Emergency Services, Public Policy, Government, Security, Technology, Software, Internet, Magnet, Forward-looking statement, NICE Ltd., Ontario Securities Commission, News, IOT, Police, Disclosure, CAD, MAGT, CX, Growth, Azure, Solution, Digital, Factor, Review, Computer, Ecosystem, Public security, Efficiency, Computer-aided dispatch, TSX, NICE, Records management, Microsoft, Organization, Partnership, Microsoft Azure, Private investigator, Audit, Magnet Forensics, NICE Public Safety, NICE, MAGNET FORENSICS, NICE PUBLIC SAFETY, NICE

NICE (Nasdaq: NICE) and Magnet Forensics (TSX: MAGT) today announced a partnership to digitally transform police case building and investigations to accelerate the pursuit of justice.

Key Points: 
  • NICE (Nasdaq: NICE) and Magnet Forensics (TSX: MAGT) today announced a partnership to digitally transform police case building and investigations to accelerate the pursuit of justice.
  • The integration of NICE Investigate and Magnet REVIEW will enable police agencies to automatically merge digital forensic evidence from Magnet REVIEW with other digital evidence sources in NICE Investigate to streamline case building and investigations.
  • Chris Wooten, Executive Vice President, NICE, commented, Were excited to partner with Magnet Forensics.
  • Now, police departments will be able to review all evidence, connected in one place, to accelerate case building, and get to the truth faster.

Gemini Therapeutics Provides GEM103 Program Update

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Health, General Health, Seniors, Pharmaceutical, Optical, Research, Genetics, Consumer, Science, Clinical Trials, Securities Act of 1933, SEC, Safety, Risk, Social media, AMD, LinkedIn, Pharmacokinetics, Patient, Factor, Time-invariant system, Forward-looking statement, Annual report, CFH, Therapy, Intravitreal injection, U.S. Securities and Exchange Commission, Biomarker, Company, File, Nasdaq, Boat, COVID-19, Twitter, Complement, Anetoderma, Pharmaceutical industry, Risk management

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103s clinical development program.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103s clinical development program.
  • Interim analysis showed that intravitreal GEM103 plus aflibercept was generally well-tolerated, and the safety profile was generally consistent with the sham plus aflibercept arm.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.

Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Health, Other Health, Medical Devices, SEC, Safety, Factor, Risk, Biologics license application, Growth, LinkedIn, Security (finance), Investment, Patient, Hospital, Â, U.S. Securities and Exchange Commission, Plasma, Awareness, IFC, Food, Food and Drug Administration, Company, Nasdaq, Technology, PAS, Transfusion medicine, Bleeding, Mission statement, Gulf Coast Regional Blood Center, COVID-19, FDA, Licensure, Corporation, BLA, CERS, EMEA, Pharmaceutical industry, Renewable energy, Cryoprecipitate, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus unaudited preliminary product revenue for the fourth quarter of 2021 totaled $39.9 million, representing an increase of 41% over the $28.2 million recognized during the fourth quarter of 2020.

Key Points: 
  • Cerus unaudited preliminary product revenue for the fourth quarter of 2021 totaled $39.9 million, representing an increase of 41% over the $28.2 million recognized during the fourth quarter of 2020.
  • The Company expects its unaudited preliminary full-year 2021 product revenue to be $130.9 million, exceeding the Companys most recent 2021 product revenue guidance range of $127-$129 million.
  • Cerus commercial momentum during the first three quarters of 2021 carried on during the fourth quarter, continuing the Companys growth trajectory.
  • This press release includes Cerus preliminary product revenue results for the quarter and year ended December 31, 2021.

Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer

Retrieved on: 
Wednesday, January 5, 2022
Therapy, University, FXI, Federal Court of Australia, Thrombosis, Factor, Fuqua, Braeburn, Anthos, Partner, Bleeding, Master of Business Administration, Duke University, Lists of diseases, CEO, High Court, Accounting, Risk, Supreme court, AF, Bachelor of Laws, Business administration, Factor XI, Pharmaceutical industry, Economics

CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ -- Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of David McIntyre as Chief Financial Officer. Mr. McIntyre will assume responsibility for the company's finance and investor relation functions, and joins Anthos as its lead product candidate, abelacimab, expects to become the first 'hemostasis-sparring' Factor XI anticoagulant to enter Phase 3 clinical studies in the United States.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ --Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of David McIntyre as Chief Financial Officer.
  • "David brings a successful track record in both public and private healthcare companies and his financial, transactional, and legal experience adds significant value to our organization going forward."
  • Anthos Therapeutics is a late-stage biotechnology company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic diseases.
  • Anthos was launched by Blackstone Life Sciences in 2019.

Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A

Retrieved on: 
Monday, December 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Hoffmann-La Roche, Phase, Headache, Poster, Blood, AE, Thrombotic microangiopathy, Protein, 1991 World Sportscar Championship, Ixa, Factor, TMA, AES, Population, Brain, TES, APCC, Woman, Thrombus, Pharmacokinetics, Lung, Head, ABR, TE, RO, Safety, Man, Patient, Leg, Exposition, Haemophilia, Ageing, Arm, VIII, Factor VIII, Bleeding, ASH, HAVEN, Skin, Society, ROG, Factor X, Pharmaceutical industry, Birth control, Genentech, Emicizumab, EU

We remain committed to working together with the hemophilia community as we further explore the efficacy and safety of Hemlibra in broader populations.

Key Points: 
  • We remain committed to working together with the hemophilia community as we further explore the efficacy and safety of Hemlibra in broader populations.
  • HAVEN 6 is a Phase III study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of Hemlibra in people with moderate or mild hemophilia A without factor VIII inhibitors.
  • This interim analysis was conducted after 50 participants with moderate hemophilia A completed at least 24 weeks in the study or withdrew.
  • These data further confirm the favorable safety profile of Hemlibra, consistent with results from previous HAVEN and STASEY studies.

Factor Secures $6 Million to Modernize Supply Chain's "First Mile" Payments Infrastructure

Retrieved on: 
Monday, December 13, 2021
Robotics, Marketing, Solution, Google, Intelligence, Life, Vecna Robotics, Technology, Growth, Stanford University, VP, Multimedia, CEO, Harvard Business School, First Mile, COVID-19, Time, Engineering, Customer success, Venture, Industry, SAN, PDF, General partnership, Factor, Cryptocurrency, Online shopping

"Most people hear 'supply chain disruption' and think of container ships stalled outside a port.

Key Points: 
  • "Most people hear 'supply chain disruption' and think of container ships stalled outside a port.
  • "This part of the supply chain transacts trillions of dollars each year and has never been more specialized, but the infrastructure that keeps it running hasn't kept pace.
  • We're revolutionizing the supply chain's First Mile by automating the process of ordering, tracking, and financing the supply of manufactured goods.
  • Based in San Francisco, Factor is building the next generation of supply chain infrastructure with a mission of making manufacturing the most innovative sector of our economy.